Jeffrey N. Weitzel

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

M. William Audeh, James Carmichael, Richard T. Penson et al. · The Lancet · 2010 · 2.3K citations

Medicine, Gynecology, Oncology +16

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Andrew Tutt, Mark E. Robson, Judy E. Garber et al. · The Lancet · 2010 · 1.6K citations

Medicine, Oncology, Pharmacotherapy +13

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Mary B. Daly, Tuya Pal, Michael P. Berry et al. · Journal of the National Comprehensive Cancer Network · 2021 · 1.1K citations · Full text

Medicine, Genetics, Oncology +17

A Population-Based Study of Genes Previously Implicated in Breast Cancer

Chunling Hu, Steven N. Hart, Rohan Gnanaolivu et al. · New England Journal of Medicine · 2021 · 866 citations · Full text

Medicine, Genetics, Molecular Genetics +17

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017

Mary B. Daly, Robert Pilarski, Michael P. Berry et al. · Journal of the National Comprehensive Cancer Network · 2016 · 661 citations · Full text

Life Sciences, Genetics, Oncology +17